Business Context and Reporting Period
This Form 8-K filing by IMMUNIC, INC. reports on the results of its annual meeting of stockholders held on June 15, 2022. The company is incorporated in Delaware and its common stock trades on The Nasdaq Stock Market LLC under the symbol IMUX.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data. There is no information provided in this document regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
The filing details the outcomes of two proposals voted upon by stockholders. A total of 29,240,383 shares were entitled to vote, with 18,395,374 shares present (in person or by proxy), constituting a quorum.
Proposal 1: Election of Directors
Stockholders elected three directors for a three-year term expiring at the 2025 annual meeting:
- Ms. Tamar Howson: 12,707,589 votes FOR; 1,338,455 votes WITHHELD.
- Dr. Jörg Neermann: 11,475,361 votes FOR; 2,570,683 votes WITHHELD.
- Mr. Barclay Phillips: 12,710,602 votes FOR; 1,355,442 votes WITHHELD.
Proposal 2: Ratification of Independent Auditor
Stockholders ratified the selection of Baker Tilly Virchow Krause, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
- FOR: 18,367,398
- AGAINST: 22,014
- ABSTAIN: 5,962
Guidance, Outlook, and Risks
This filing does not provide management commentary, financial guidance, outlook, or a discussion of risks and contingencies. It is strictly limited to the reporting of the stockholder vote results.
Key Facts for Investor Verification
- Verify the tenure of the newly elected directors (Tamar Howson, Jörg Neermann, Barclay Phillips) through the 2025 annual meeting.
- Confirm the engagement of Baker Tilly Virchow Krause, LLP for the 2022 fiscal year audit.
- Note that this document contains no financial metrics; refer to the most recent 10-K or 10-Q for financial performance data.